PPIG and metabolic dysfunction-associated steatohepatitis: Furthermore, the effect of liver disease, including non-alcoholic fatty liver disease (NAFLD) and its complication non-alcoholic steatohepatitis (NASH), on the metabolism of drugs, especially cytochrome P450 (CYP)-mediated phase 1 reactions [6], has been investigated in both preclinical [7] and clinical studies [8,9].